MBX Biosciences, Inc.

MBX

Held by 5 specialist biotech funds

High Convergence

Share on X

Fund Holdings

5 fund convergence

Driehaus Capital Rock Springs Capital EcoR1 Capital

Position Trend

Feb 13, 2026

$28.1M

1 fund

Feb 17, 2026

$244.4M

4 funds

+771% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 1,408,159Value: $44.4M

**MBX Signal Note:** Driehaus's $44.4M initiation in MBX signals confidence in the company's clinical pipeline, likely driven by upcoming Phase 2 readouts for MBX8859 (oral GLP-1 agonist) and MBX2082 (oral TAFI inhibitor for thrombosis). The entry size and Driehaus's biotech expertise suggest conviction in oral formulation advantages and commercial potential in high-value indications, with near-term catalysts expected in 2024-2025.

Rock Springs CapitalNEWFeb 17, 2026

More MBX Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

RNA3 funds ALNY3 funds IMNM3 funds EW3 funds LLY3 funds PTCT3 funds BBIO3 funds CRNX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Rock Springs Capital Initiates MBX Position Rock Springs' $8.9M entry into MBX Biosciences signals conviction in the company's pipeline, likely driven by upcoming clinical catalysts in its lead programs (MBX8859 for NASH and MBX2328 for autoimmune diseases). The concentrated healthcare investor's initiation suggests positive interim data expectations or favorable risk/reward ahead of near-term readouts. Given Rock Springs' long/short discipline, this represents meaningful fundamental validation rather than passive accumulation.